Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Texting your way to better diabetes control? new trial tests SMS gum care reminders.

NCT ID NCT07165171

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether sending SMS reminders and advice to people with type 2 diabetes and gum disease can improve their blood sugar control over two years. 516 adults who recently completed gum disease treatment will be split into two groups: one gets standard follow-up, the other gets text messages with medical info, questions, and appointment reminders. The main goal is to see if the SMS group has lower HbA1c levels, a key measure of blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SMS text message reminders and advice
What this could lead to
If it works, this could offer a simple, low-cost way to improve blood sugar control in people with type 2 diabetes and gum disease.
What could go wrong
This is an early-stage trial testing a behavioral intervention, not a drug. The effect may be small or not last, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 516 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \-- Adult aged 18 years or older; * Presenting with type 2 diabetes (under ALD), balanced or not, for 6 months or more; * Having been treated in the previous 6 months for periodontitis (stages 1 to 4 according to the new classification of periodontal and peri-implant diseases EFP-AAP 2018) in one of the participating centers and presenting a clinical situation allowing the transition to the periodontal follow-up phase (; (absence or limited number of sites presenting clinical signs of persistent periodontal inflammation) * Presenting more than 6 teeth; * Possessing a smartphone or tablet with internet access; * Affiliated to social security; * Patient able to read, write and understand French * Having signed a consent to participate in the study. Exclusion Criteria: * Patient presenting uncontrolled systemic diseases and diagnosed for less than 6 months or presenting a major aggravation of a systemic pathology according to the judgment of the investigator. * Pregnant or breastfeeding women; * Persons deprived of liberty by a judicial or administrative decision; * Adults subject to a legal protection measure (guardianship, curatorship).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Periodontal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

periodontal disorder periodontitis type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Periodontal disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cabinet libéral

    Saint-Victor-de-Cessieu, 38110, France

  • Centre Hospitalo-Universitaire de Lille

    Lille, 59000, France

  • Centre Hospitalo-Universitaire de Nantes

    Nantes, 44000, France

  • Centre Hospitalo-Universitaire de Rennes

    Rennes, 35000, France

  • Centre Hospitalo-Universitaire de Toulouse

    Toulouse, 31300, France

  • Hospices Civils de Lyon, Centre de Soins Dentaires.

    Lyon, 69007, France

  • Hôpital Charles Foix

    Ivry-sur-Seine, 94200, France

  • Hôpitaux universitaires de Strasbourg

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.